D.E. Shaw & Co
AEGR

D.E. Shaw & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

D.E. Shaw & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-20,100
Closed -$421K – 4247
2014
Q4 		$421K Sell
20,100
-12,500
-38% -$315K ﹤0.01% 3443
2014
Q3 		$1.09M Buy
32,600
+12,500
+62% +$388K ﹤0.01% 2726
2014
Q2 		$645K Sell
20,100
-31,500
-61% -$1.17M ﹤0.01% 3308
2014
Q1 		$2.38M Buy
51,600
+31,500
+157% +$1.85M ﹤0.01% 2212
2013
Q4 		$1.43M Sell
20,100
-3,700
-16% -$283K ﹤0.01% 2847
2013
Q3 		$2.04M Buy
23,800
+20,100
+543% +$1.7M ﹤0.01% 2399
2013
Q2 		$234K Buy
+3,700
New +$196K ﹤0.01% 3697

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

D.E. Shaw & Co's AEGR Position: Q4 2015 in Review

D.E. Shaw & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 31,116 shares — an estimated $423K sold.

D.E. Shaw & Co first reported a position in AEGR in Q2 2013 and held it in 10 quarters. The position peaked at $9.12M in Q3 2014. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • D.E. Shaw & Co reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • D.E. Shaw & Co sold 31,116 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $423K.
  • D.E. Shaw & Co first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • D.E. Shaw & Co's Aegerion Pharmaceuticals position peaked at $9.12M in Q3 2014.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on D.E. Shaw & Co's 13F filing for Q4 2015, filed 16 Feb 2016.